Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2026
Pharma News, 2026
Akari Therapeutics Reveals Breakthrough AKTX-101 Synergy in KRAS Cancers
Akari Therapeutics announces breakthrough preclinical data showing AKTX-101, a TROP2-targeting ADC, synergizes with KRAS inhibitors in pancreatic cancer.
Verdiva Bio Preclinical Obesity Drug Data Slated for ADA 86th Sessions
Verdiva Bio to present preclinical data for oral obesity drugs VRB-103 and VRB-104 at the American Diabetes Association 86th Scientific Sessions in June.
US FDA Approves AstraZeneca's Baxfendy for Uncontrolled Hypertension Care
The US FDA approved AstraZeneca’s Baxfendy, a first-in-class aldosterone synthase inhibitor, for adults with resistant and uncontrolled hypertension.
Risen Pharma Starts Phase 2 Trial of RP902 for Mild Cognitive Impairment
Risen Pharma announces a Phase 2 clinical trial in China for RP902, an oral small-molecule drug targeting Alzheimer's disease patients with the ApoE ε4 gene.
Osteosarcoma Drug FL118 Earns FDA Orphan & Rare Pediatric Disease Status
The FDA granted rare pediatric disease and orphan drug designations to FL118, a novel camptothecin derivative for osteosarcoma developed by Roswell Park.
Sonire Therapeutics Starts US Pancreatic Cancer Focused Ultrasound Trial
Stanford University begins a clinical trial testing Sonire Therapeutics' focused ultrasound system, SUNRISE-II, for unresectable pancreatic cancer treatment.
Preclinical Models Map Genetic Changes Behind Multiple Sclerosis Damage
University of Notre Dame researchers empirically compare CPZ and LPC preclinical models to study myelin loss and regeneration in multiple sclerosis.
FDA Approves First All-Oral Inqovi and Venclexta Regimen for AML Care
The FDA approved the all-oral combination of Inqovi and Venclexta for newly diagnosed acute myeloid leukemia in adults 75 or older or chemo-ineligible.
GSK Signs Three-Year Agreement with Protas to Streamline Clinical Trials
GSK enters a new 3-year partnership with Protas to improve the quality, speed, and efficiency of late-stage clinical trials across core therapeutic areas.
Regeneron Inks $2.3B Deal with Parabilis for Novel ADC-Like Therapies
Regeneron partners with Parabilis Medicines in a $2.3 billion deal to develop antibody-Helicon conjugates, a novel class of precision targeted therapies.
Harbour BioMed Preclinical Data Challenges Eli Lilly in Obesity Space
Harbour BioMed publishes preclinical data on LET003, an ACVR2A/2B antibody, showing promise as a rival to Eli Lilly's bimagrumab in obesity treatment.
Global Economic Impact: Tuberculosis Costs the World $1.35 Trillion a Year
New research reveals tuberculosis costs the world $1.35 trillion annually, draining 0.8% of global economic potential and heavily impacting poorer nations.
4
5
6
7
8
9
10
11
12
